Jascayd (Nerandomilast) Receives FDA Approval as New Molecular Entity

The U.S. Food and Drug Administration (FDA) granted initial approval to Jascayd (nerandomilast) on October 7, 2025. This approval marks nerandomilast as a Type 1 - New Molecular Entity, indicating it is an entirely new active ingredient not previously marketed in the United States.

Background

Jascayd (nerandomilast) is sponsored by Boehringer Ingelheim. As a Type 1 - New Molecular Entity, its approval signifies a novel therapeutic agent entering the market.

What this means

The FDA's initial approval of Jascayd (nerandomilast) as a New Molecular Entity provides a new treatment option for patients. This designation highlights the drug's novel composition and potential to address unmet medical needs.

Source

The information regarding the approval of Jascayd (nerandomilast) was sourced from the U.S. Food and Drug Administration (FDA). This approval was documented on October 7, 2025, on the accessdata.fda.gov website.